slides · global inventory
Evidence Matrix
Framework collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 335
Current window 271-300
Pages 12
Rows per page 30
Framework
271-300 of 335
33
Includes a Kaplan-Meier survival curve as evidence for the clinical relevance of TLS.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations 1 hit
08
Includes two distinct charts: a scatter/error bar plot for Phase 1 and a bar chart for the Canine Model.ATAI | Investor Presentation Deck | 31 slides · atai Life Sciences
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
28
The slide uses a grouped bar chart to visualize T-scores across three cognitive tests (HVLT, Symbol Coding, Category Fluency) for four dosage cohorts.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
30
The slide presents clinical evidence linking AXL expression to poor patient outcomes in two different cohorts.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
99
Uses a dot-matrix visualization to highlight skill gaps (red dots) vs. strengths (green dots).Blackwells Capital | Activist Presentation Deck | 101 slides · Blackwells Capital
Activist deck Activist investor 1 hit
17
The slide uses a stacked bar chart to show amplification types and a Kaplan-Meier survival curve to show patient outcomes.Boundless Bio | IPO Presentation Deck | 51 slides · Boundless Bio
Pitch deck Investment bank 1 hit
38
The slide uses a table structure to map initial drivers to resistance mechanisms, supported by clinical citations and microscopy images.Boundless Bio | IPO Presentation Deck | 51 slides · Boundless Bio
Pitch deck Investment bank 1 hit
57
The slide uses a heatmap to visualize synergy (green) vs no synergy (light green) across 6 different drug combinations.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
52
The slide uses a color-coded heatmap to visualize performance against criteria.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
14
Includes a comparison table of historical data vs ELAHARE and a specific VIRO-15 clinical outcome table.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
19
Includes Kaplan-Meier survival curves and dose escalation scatter plots for two distinct patient groups.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
34
The slide uses a bubble chart to map clinical trial outcomes against patient treatment history and a table to detail specific drug performance metrics.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
39
The slide uses a bubble chart to map clinical trials and a table to summarize drug performance metrics, highlighting low efficacy and high toxicity.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
49
The slide uses a bubble chart to map clinical trials and a table to detail drug performance metrics.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
52
Includes a comparative diagram of the drug molecule vs standard IgG antibody and multiple clinical/preclinical data charts.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
09
The slide uses academic citations to validate the mechanism of action for their CAR-T design.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · InterestLoop · Logic Chain1 hit
11
The slide compares HSL (Heavy-chain-led) vs LSH (Light-chain-led) configurations using bar charts for expansion and cytotoxicity metrics.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
59
The slide uses a combination of expert testimonials and a comparative table of clinical trials to validate the outpatient administration model.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
51
The slide uses a bubble chart to map clinical trial outcomes and a table to detail specific drug performance metrics across treatment lines.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
25
Includes detailed clinical trial citations in the footer.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Market Sizing1 hit
46
The bubble chart maps mPFS against patient treatment history; the table highlights poor outcomes and high toxicity across lines of therapy.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
40
Uses screenshots of news articles as evidence of market trends.Innovid | Investor Day Presentation Deck | 74 slides · Innovid
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
18
The slide presents two line charts showing tumor volume reduction over time, highlighting 100% complete response (CR) and resistance to tumor rechallenge.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
11
The slide uses data from a 2022 JNCI study to justify the clinical importance of AA detection sensitivity.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
11
The slide uses data from a 2022 JNCI study to justify the clinical importance of AA detection sensitivity.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
12
Uses data from Ladabaum U, et al. (JNCI, 2022) to justify the importance of AA detection thresholds.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
12
The slide uses a table to establish clinical credibility for the MM-120 program by citing historical and contemporary research.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations 1 hit
10
The slide uses a 'Case Study' framework to validate the strategy by comparing it to the established success of Osimertinib in EGFR+ NSCLC.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · SolutionLoop · Pattern Hunter1 hit
24
The chart shows pharmacokinetic data across five dose cohorts, demonstrating that the 150mg dose consistently stays above the predicted CNS efficacy thresholds.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
11
Includes citation references and a 'Newly published' callout for the Abington Hospital study.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations 1 hit